Achieve Lasting Weight Loss
The problem isn't discipline — it's biology. Elevated cortisol, dysregulated hunger hormones, and circadian misalignment create metabolic conditions that no amount of willpower can overcome alone. GLP-1 medications work with your hormonal systems to correct the root causes, not just the symptoms.
How GLP-1 Medications Work
GLP-1 medications work with your body's natural systems to reduce appetite and promote lasting weight loss.
Slows digestion
GLP-1 slows gastric emptying, helping you feel full longer after meals and reducing overall calorie intake.
Regulates appetite
Signals your brain's hunger centers to reduce appetite and cravings, making it easier to stick to healthy eating.
Improves metabolism
Enhances insulin sensitivity and helps your body process glucose more efficiently, supporting healthy weight management.
Slows digestion
GLP-1 slows gastric emptying, helping you feel full longer after meals and reducing overall calorie intake.
Regulates appetite
Signals your brain's hunger centers to reduce appetite and cravings, making it easier to stick to healthy eating.
Improves metabolism
Enhances insulin sensitivity and helps your body process glucose more efficiently, supporting healthy weight management.
Choose Your Treatment
Tirzepatide
The most effective GLP-1/GIP dual agonist for significant weight loss
- Most effective weight loss medication available
- Dual GLP-1/GIP action for enhanced results
- Up to 20.9% body weight reduction in clinical trials¹
Semaglutide
Proven GLP-1 medication for effective weight management
- Clinically proven 14.9-17.4% weight loss²
- Once-weekly injection
- Reduces hunger and cravings
Tirzepatide
The most effective GLP-1/GIP dual agonist for significant weight loss
- Most effective weight loss medication available
- Dual GLP-1/GIP action for enhanced results
- Up to 20.9% body weight reduction in clinical trials¹
Semaglutide
Proven GLP-1 medication for effective weight management
- Clinically proven 14.9-17.4% weight loss²
- Once-weekly injection
- Reduces hunger and cravings
Tirzepatide vs. Semaglutide: Which is Right for You?
Choose Tirzepatide if:
- You want maximum weight loss results (up to 20.9% in clinical trials¹)
- You prefer the dual GLP-1/GIP mechanism
- Cardiovascular benefits (reduced major cardiac events)³ or obstructive sleep apnea⁴
- You have significant weight to lose
Both medications are administered once weekly via subcutaneous injection. Our medical team will help you determine the best option based on your health history and goals.
RespondWell does not represent any compounded product as being equivalent to, or associated with, any branded or FDA-approved drug product.
Frequently Asked Questions
About GLP-1 Weight Loss Treatment
About RespondWell
About Our Medications
Our treatments contain active pharmaceutical ingredients that conform to USP (United States Pharmacopeia) monograph standards and are custom-compounded by licensed 503A and 503B pharmacies to meet your individual needs. Compounded medications are not FDA-approved finished drug products. The suggested formulations are provided for reference only and are based on formulations that have historically been prescribed by duly licensed prescribers. All medications are prepared in accordance with a valid prescription from a licensed healthcare provider following a medical consultation.
Medical Consultation Required
Our licensed medical providers will evaluate your health history and goals to determine the most appropriate treatment option for you. Prescriptions are subject to medical evaluation and are not guaranteed. If we are unable to prescribe treatment after your consultation, you pay zero. Independent clinical services provided by: Wasef Health, PC c/o Michael Wasef MD. Licensed in all 50 states + DC.
Clinical References
- 1Jastreboff AM, et al. SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
- 2Wilding JPH, et al. STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
- 3Del Prato, S., Kahn, S. E., Pavo, I., et al. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). The Lancet, 398(10313), 1811–1824.
- 4Malhotra, A., Grunstein, R. R., Gao, L., et al. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine, 391(13), 1193–1205.